Press Releases

Date	Title and Summary	View
Dec 07, 2020	MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting 53.8% ORR in relapsed/refractory DLBCL patients Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date ROCKVILLE, MD , Dec. 07, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company
Dec 06, 2020	MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting 31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patients Median duration of response = 8.13 months ROCKVILLE, MD , Dec. 06, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing
Nov 30, 2020	MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expenses EVERSANA may earn revenue share payments over five years subject to predefined cap MacroGenics’ projected cash runway remains into 2023 ROCKVILLE, MD and CHICAGO, IL , Nov.
Nov 30, 2020	MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte ROCKVILLE, MD , Nov. 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that $25 million in milestones have
Nov 09, 2020	MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD , Nov. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Nov 04, 2020	MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Nov 04, 2020	MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020 ROCKVILLE, MD , Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced six clinical and preclinical abstracts
Oct 28, 2020	MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call ROCKVILLE, MD , Oct. 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Oct 15, 2020	MacroGenics Announces Flotetuzumab Publication in Blood Advances — Role of TP53 abnormalities in immunotherapy response in AML highlighted ROCKVILLE, MD , Oct. 15, 2020 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the
Sep 23, 2020	MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics Manuscript describes preclinical development of MGC018 Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD , Sept. 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical
Sep 22, 2020	MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood ROCKVILLE, MD , Sept. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript in
Sep 21, 2020	MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte $15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by Incyte ROCKVILLE, MD , Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based
Sep 20, 2020	MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020 MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibition Recommended Phase 2 dose established for MSS CRC, NSCLC expansion cohorts Presentation is available on-demand as part of the ESMO Virtual Congress 2020 ROCKVILLE, MD ,
Sep 03, 2020	MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD , Sept. 03, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Aug 05, 2020	MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD , Aug. 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Jul 30, 2020	MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , July 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Jul 23, 2020	MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call Rockville, MD , July 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Jul 09, 2020	MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer Rockville, MD , July 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that Lancet Oncology has published
Jun 22, 2020	MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting Rockville, MD , June 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American
Jun 16, 2020	MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer Rockville, MD , June 16, 2020 (GLOBE NEWSWIRE) -- Stephen Eck appointed Chief Medical Officer of MacroGenics MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of
Jun 05, 2020	MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer Rockville, MD , June 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S.
Jun 03, 2020	MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia Rockville, MD , June 03, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced research published in the journal
May 28, 2020	MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer - Advisory committee meeting not required; PDUFA goal date unchanged Rockville, MD , May 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the
May 27, 2020	MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia Rockville, MD , May 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced plans for a clinical study intended to
May 21, 2020	MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO Rockville, MD , May 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a conference call and audio